CANNAINVESTOR Magazine February / March 2017 - Page 15

15

Regulators and medical professionals globally are also recognizing the range of disease indications with which medical cannabis is assisting. The prestigious US National Academy of Sciences, earlier this year, released the biggest independent review based on the level of research currently undertaken on the health effects of cannabis.

This is important information for the sector as we see the push worldwide for changing the legal landscape. Some of the review’s findings concluded that there was evidence that cannabis/cannabinoids are effective for treatment of sleep disorders, however there was no conclusive research on the effects on cancer¹.

The report highlights the importance of expanding and improving the quality of cannabis research efforts so as to provide conclusive evidence of the efficacy of medical cannabis in treating various medical conditions.

This focus on running robust clinical trials and building knowledge via pre-clinical research activities positions Zelda as one of the small number of companies operating in this manner in the global medicinal cannabis sector. Combined with a commitment to building a diversified intellectual property portfolio Zelda is laying very strong foundations for future value creation for shareholders.

1 National Academies of Sciences, Engineering, and Medicine. 2017. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press. doi:10.17226/24